# BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon

> **NCT02247310** · — · COMPLETED · sponsor: **Bayer** · enrollment: 498 (actual)

## Conditions studied

- Multiple Sclerosis, Relapsing Remitting

## Interventions

- **DRUG:** Interferon beta-1b (Betaferon®, BAY 86-5046)
- **DEVICE:** BETACONNECT

## Key facts

- **NCT ID:** NCT02247310
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-20
- **Primary completion:** 2016-07-19
- **Final completion:** 2016-11-08
- **Target enrollment:** 498 (ACTUAL)
- **Last updated:** 2017-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02247310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02247310, "BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02247310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*